Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
D 121.12 -1.37% -1.68
ASND closed down 1.37 percent on Friday, May 17, 2024, on 1.98 times normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Calm After Storm Range Contraction -1.37%
Lower Bollinger Band Walk Weakness -1.37%
Below Lower BB Weakness -1.37%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ascendis Pharma A/S Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Breakthrough Therapy Pulmonary Arterial Hypertension Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil

Is ASND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 161.0
52 Week Low 83.75
Average Volume 348,799
200-Day Moving Average 119.18
50-Day Moving Average 142.53
20-Day Moving Average 134.81
10-Day Moving Average 129.53
Average True Range 5.33
RSI (14) 25.37
ADX 35.3
+DI 7.65
-DI 36.55
Chandelier Exit (Long, 3 ATRs) 131.47
Chandelier Exit (Short, 3 ATRs) 132.60
Upper Bollinger Bands 148.35
Lower Bollinger Band 121.26
Percent B (%b) -0.01
BandWidth 20.10
MACD Line -5.46
MACD Signal Line -4.06
MACD Histogram -1.4029
Fundamentals Value
Market Cap 6.86 Billion
Num Shares 56.6 Million
EPS -9.21
Price-to-Earnings (P/E) Ratio -13.15
Price-to-Sales 30.12
Price-to-Book 14.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 128.23
Resistance 3 (R3) 128.65 126.71 127.05
Resistance 2 (R2) 126.71 124.90 126.50 126.65
Resistance 1 (R1) 123.91 123.78 122.94 123.49 126.25
Pivot Point 121.97 121.97 121.48 121.76 121.97
Support 1 (S1) 119.17 120.16 118.20 118.75 115.99
Support 2 (S2) 117.23 119.04 117.02 115.59
Support 3 (S3) 114.43 117.23 115.20
Support 4 (S4) 114.01